Streetbeat News

Regulatory

CRBU

Caribou Biosciences has announced that the FDA has cleared its IND application for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia.

Portfolio Pulse from Bill Haddad

October 18, 2023 | 12:00 pm

PTN

Palatin Technologies is planning to initiate a clinical study of Melanocortin 4 Receptor Agonist + GLP-1 in obese patients. The company has reported preclinical data showing synergistic weight loss.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:37 am

BABA

JD

KWEB

NVDA

Alibaba Group Holding Limited (BABA) stock is trading lower in line with the broader index KraneShares CSI China Internet ETF (KWEB) after the U.S. imposed stricter restrictions on China's access to advanced artificial intelligence chips from American technology companies like Nvidia Corp (NVDA). JD.Com, Inc (JD) launched a four-hour express delivery in Hong Kong, increasing competition against Alibaba's logistics arm Cainiao. Alibaba.com is courting merchants from ByteDance-owned TikTok catering to Southeast Asia after suspending e-commerce activities in Indonesia.

Portfolio Pulse from Anusuya Lahiri

October 18, 2023 | 11:16 am

ZVSA

ZyVersa Therapeutics has announced the publication of an article in the peer-reviewed journal, Aging, which demonstrates that inflammasome NLRP3 activation is associated with an age-related decline in kidney health.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:13 am

MA

V

The Federal Reserve is planning to introduce a proposal to reduce the fees merchants pay to banks for debit card transactions. This could impact major card issuers like Mastercard (MA) and Visa (V), who have been charging a fee of 21 cents plus 0.05% of the total transaction value for each transaction. The Durbin amendment, which introduced this fee cap, has led to a shift in the payments sector, reducing the influence of networks like Visa and Mastercard in setting interchange fees.

Portfolio Pulse from Anusuya Lahiri

October 18, 2023 | 11:11 am

TNXP

Tonix Pharmaceuticals announced that a study published in the Journal Nature by Center for Transplantation Sciences Faculty, Massachusetts General Hospital and Egenesis, utilized TNX-1500 as part of immune modulating regimen to prevent organ transplant rejection.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:10 am

ASLN

ASLAN Pharmaceuticals is set to co-host a KOL panel discussion on changes in clinical trial and treatment landscape for Atopic Dermatitis on October 24, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:07 am

TLSA

The U.S. Food and Drug Administration (FDA) has approved at-home dosing of Intranasal Foralumab for multiple sclerosis patients. This decision was announced by Tiziana Life Sciences.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:02 am

NTLA

Intellia Therapeutics has received FDA clearance for its IND application to initiate a pivotal Phase 3 trial of NTLA-2001 for the treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:01 am

AAPL

MSFT

TSLA

Microsoft CEO Satya Nadella has expressed concerns about the potential dangers of artificial intelligence (AI) and called for guidance from moral philosophers and developers. He compared AI to cars and airplanes, which are regulated and used within well-defined laws, suggesting a need for AI regulation. Earlier this year, over 1000 tech experts, including Elon Musk and Steve Wozniak, signed an open letter calling for a pause in AI developments until safety protocols are created.

Portfolio Pulse from Rounak Jain

October 18, 2023 | 10:45 am